Novavax Q1 Revenue Hits $139.5M, Beating Estimates on Vaccine Deals Strength
NVAX sits 48% above its 52-week low of $5.8.
Summary
Novavax reported first-quarter revenue of $139.5 million, significantly exceeding analysts' estimates of $78.3 million. This strong performance was primarily driven by milestone payments from vaccine supply and licensing deals, helping to offset broader demand pressures. This news follows the company's 10-Q filing on the same day, which detailed a net loss of $9.5 million for Q1 2026 and a new $330 million credit facility. The substantial revenue beat is a positive development, indicating better-than-expected performance in its core vaccine business and could provide a boost to investor confidence. Traders will now focus on the sustainability of these vaccine deals and the company's path to profitability.
At the time of this announcement, NVAX was trading at $8.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $5.80 to $11.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.